EMERYVILLE, Calif. (May 4, 2017) – NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 first quarter financial results after market close on Thursday, May 11. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.
DATE: Thursday, May 11
TIME: 4:30 p.m. ET / 1:30 p.m. PT
DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 14535369
The live call also will be available at https://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 12:59 p.m. Eastern time June 11, 2017, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 14535369. The call will also be archived at https://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® lid and lash hygiene for the eye care market. Avenova is formulated with Neutrox®, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure hypochlorous acid. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.
From the Company
Thomas J. Paulson
Chief Financial Officer